| 纯度 | >90%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | Gzmc |
| Uniprot No | P08882 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-248aa |
| 氨基酸序列 | IIGGNEISPHSRPYMAYYEFLKVGGKKMFCGGFLVRDKFVLTAAHCKGSSMTVTLGAHNIKAKEETQQIIPVAKAIPHPDYNPDDRSNDIMLLKLVRNAKRTRAVRPLNLPRRNAHVKPGDECYVAGWGKVTPDGEFPKTLHEVKLTVQKDQVCESQFQSSYNRANEICVGDSKIKGASFEEDSGGPLVCKRAAAGIVSYGQTDGSAPQVFTRVLSFVSWIKKTMKHS |
| 预测分子量 | 32.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Gzmc(Granzyme C)重组蛋白的虚构参考文献示例，供参考：
---
1. **文献名称**: *Recombinant Granzyme C Expression in E. coli: Purification and Functional Characterization*
**作者**: Zhang Y, et al.
**摘要**: 本研究报道了通过大肠杆菌系统高效表达和纯化重组Gzmc蛋白的方法，并验证其蛋白酶活性。研究发现，重组Gzmc可特异性切割胱天蛋白酶(caspase)相关底物，提示其在细胞凋亡通路中的潜在作用。
2. **文献名称**: *Granzyme C Enhances Cytotoxic Lymphocyte-Mediated Tumor Cell Killing*
**作者**: Smith JL, et al.
**摘要**: 通过体外实验证明，重组Gzmc与穿孔素(perforin)协同作用可增强CD8+ T细胞对肿瘤细胞的杀伤效率。研究揭示了Gzmc在抗肿瘤免疫中的独特机制，区别于Granzyme B的经典凋亡通路。
3. **文献名称**: *Structural Insights into Substrate Specificity of Recombinant Granzyme C*
**作者**: Lee H, et al.
**摘要**: 利用X射线晶体学解析了重组Gzmc的三维结构，发现其底物结合口袋的独特构象，解释了其对特定多肽序列的选择性切割能力。研究为设计Gzmc特异性抑制剂提供了结构基础。
---
**备注**：以上文献为示例性内容，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实发表的论文。
Granzyme C (GzmC), a member of the granzyme family of serine proteases, is primarily expressed by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. It is stored in cytotoxic granules alongside perforin and other granzymes, playing a role in immune-mediated apoptosis of virus-infected or malignant cells. Upon immune cell activation, GzmC is released into the immunological synapse and delivered into target cells via perforin-dependent pore formation. Once internalized, it cleaves specific intracellular substrates to initiate caspase-dependent or independent apoptotic pathways, though its precise mechanisms remain less characterized compared to granzymes A and B.
Recombinant GzmC protein is generated through molecular cloning techniques, typically by inserting the human GzmC gene into expression vectors (e.g., bacterial, insect, or mammalian systems) to produce purified, bioactive protein. This engineered protein retains enzymatic activity and structural stability, enabling in vitro studies of its substrate specificity, signaling pathways, and interactions with endogenous inhibitors like serine protease inhibitors (serpins).
Research on recombinant GzmC has gained momentum due to its potential therapeutic applications. Unlike GzmB, which shows broad pro-apoptotic effects, GzmC exhibits more restricted substrate selectivity, suggesting unique roles in immune regulation and tumor surveillance. Studies explore its utility in cancer immunotherapy, particularly in overcoming tumor resistance to conventional apoptosis-inducing agents. Additionally, recombinant GzmC serves as a tool to investigate antiviral responses and autoimmune disorders linked to dysregulated granzyme activity. Current challenges include optimizing delivery systems to target specific cells and minimizing off-target effects, which are critical for translational applications.
×
